While tumor genome sequencing has become widely available in clinical and research settings, the interpretation of tumor somatic variants remains an important bottleneck. Most of the alterations observed in tumors, including those in well-known cancer genes, are of uncertain significance. Moreover, the information on tumor genomic alterations shaping the response to existing therapies is fragmented across the literature and several specialized resources. Here we present the Cancer Genome Interpreter (http://www.cancergenomeinterpreter.org), an open access tool that we have implemented to annotate genomic alterations and interpret their possible role in tumorigenesis and in the response to anti-cancer therapies.
procedure. One of its major bottlenecks is identifying the driver alterations. A widely employed approach to solve this hurdle consists in focusing on the mutations affecting known cancer genes, i.e., tumor suppressors and oncogenes. These were initially identified through experimentation, giving rise over the past 40 years to a census of human cancer genes 2 . More recently, large re-sequencing projects have provided the opportunity to systematically identify the genes involved in tumorigenesis by detecting signals of positive selection in their alterations pattern across about two dozen malignancies [3] [4] [5] [6] . Nevertheless, many somatic variants in tumors, even those in cancer genes, still have uncertain significance and thus it is not clear whether or not they are drivers. Another hurdle in the interpretation of cancer genomes concerns one of its crucial aims: the identification of tumor alterations that may affect treatment options. Unstructured information on the effectiveness of therapies targeting specific cancer drivers is continuously generated by clinical trials and preclinical experiments. In summary, novel computational tools are required to address the two aforementioned critical challenges. This includes, on the one hand, methods to estimate the oncogenic effect of the variants observed in a tumor (i.e., identifying validated driver variants and providing some estimation for variants of unknown significance), and on the other, resources that systematically gather the information on biomarkers of drug response and organize them according to distinct use requirements.
The Cancer Genome Interpreter
Here, we describe the Cancer Genome Interpreter (CGI), a platform that systematizes the interpretation of cancer genomes and makes it automatic. The specific aim of the CGI is to determine which alterations observed in a tumor are more likely to be drivers and identify those that may constitute biomarkers of response to therapies ( Fig. 1 ; details in Supp. Note I). CGI relies on existing knowledge collected from several resources and on computational methods that annotate the alterations in a tumor according to distinct levels of evidence. The tool is a freely available web-resource under an open license, which is intended to facilitate its use by cancer researchers and medical oncologists (http://cancergenomeinterpreter.org). In the following sections we present a blueprint for the interpretation of cancer genomes and describe its implementation in the CGI.
A comprehensive catalog of cancer genes across tumor types
One of the main aims of the interpretation of cancer genomes is to identify the alterations responsible for oncogenic traits. We propose that this process begins with a focus on alterations that affect the genes capable of driving the growth of a particular tumor type. Therefore, we compiled a catalog of genes involved in the onset and progression of different types of cancer, obtained via different methods and from different sources (Supp. Note II). First, we collected genes that have been experimentally or clinically verified to drive tumorigenesis from manually annotated resources 2,7-10 and the literature. Second, we exploited the bioinformatics results from the analysis of large tumor cohorts re-sequenced by international efforts such as The Cancer Genome Atlas and the International Cancer Genome Consortium 11, 12 . On detail, we identified genes whose somatic alterations exhibit signals of positive selection across 6,729 tumors representing 28 types of cancer 4 . In addition, we retrieved the mode of action of each of these cancer genes (i.e., whether they function as an oncogene or a tumor suppressor), curated following state-of-the art knowledge when available and otherwise estimated in silico 13 . The resulting Catalog of Cancer Genes currently comprises 837 genes with some evidence of being drivers in 193 different cancer types ( Fig. 2a ). We annotated each of these genes, identifying (i) the malignancies it drives, organized according to available evidence; (ii) the types of alterations involved (mutations, copy number alterations and/or gene translocations); (iii) the original source(s) reporting it; (iv) the context (germline or somatic) in which these alterations are tumorigenic; and
(v) its mode of action as appropriate. The Catalog is available for download through the CGI website (https://www.cancergenomeinterpreter.org/genes).
Most mutations affecting cancer genes are of uncertain significance
A key aspect of assessing the mutations observed in cancer genes is the tumorigenic potential of each individual variant, as not all of them are necessarily capable of driving tumorigenesis. Therefore, the CGI next focuses on protein affecting mutations (PAMs) that occur in genes of the Catalog of Cancer Genes.
Validated tumorigenic mutations may confidently be labeled as drivers when detected in a tumor. We compiled an inventory that currently contains 3,939 such validated driver or cancer predisposing variants from dedicated resources [7] [8] [9] [10] 14 and the literature ( Fig. 2B tumorigenesis, a proportion that varies widely per gene and tumor type ( Fig. 2c and Supp Note VII). This highlights the need for a means to estimate the tumorigenic potential of these variants. We reasoned that several features of each specific mutation as well as of the genes affected by them could help address this question. Moreover, we propose that some of these features of interest can be extracted from the analyses of large sequenced cohorts of healthy and tumor tissue 4, 15 . Examples of relevant attributes include the following:
i) the tumorigenic mode of action of the gene in that cancer (oncogene or tumor suppressor); ii) the consequence type of the mutation (e.g. synonymous, missense or truncating); iii) its position within the transcript; iv) whether it falls in a mutational hotspot or cluster; v) its predicted functional impact; vi) its frequency within the human population; and vii) whether it occurs in a domain of the protein that is depleted of germline variants. The CGI assesses the tumorigenic potential of the variants of unknown significance via
OncodriveMUT, a rule-based approach that combines the values of these features ( Fig. 1C ; Supp. Note IVa).
To assess the performance of OncodriveMUT in the task of classifying driver and passenger mutations, we used the Catalog of Validated Oncogenic Mutations (n=3,939) and a collected set of neutral PAMs affecting cancer genes (n=1,247). We found that OncodriveMUT separates the variants of these two data sets with 91% of accuracy (Matthews correlation coefficient, 0.78) (Supp Note IVb). Furthermore, the predictions of
OncodriveMUT exhibited a high concordance with the results of experiments assessing the tumorigenic effect of other mutations that are uncommonly seen in cancer [16] [17] [18] [19] (Supp Note IVb). In summary, the CGI annotates the mutations affecting cancer genes with features relevant to their potential role in cancer to facilitate the user's review, identifying validated drivers and classifying the most likely drivers among the variants of unknown significance.
A database of genomic determinants of anti-cancer drug response
The second major aim of the effort to interpret cancer genomes is to identify which of the tumor alterations may shape the response to anti-cancer therapies. Findings about the influence of genomic alterations on drug response are continuously generated and reported through publications, clinical trials and conference communications. The challenge resides in gathering relevant results into an easy-to-use resource, and organizing them according to the needs of different users. The CGI employs two resources to explore the associations between gene alterations and drug responses. The first is the Cancer Biomarkers database, an extension of a previous collection of genomic biomarkers of anti-cancer drug response 8 The use of the CGI to automatically interpret cancer genomes has broad potential applications, ranging from basic cancer genomics to the translational setting. One feature of the CGI that makes it particularly suitable to different types of applications is its flexibility. The user can input tumor alterations by uploading files following different standards and/or by typing them in a free-text box. The system is prepared to automatically recognize and re-map as necessary different formats, such as genomic, transcript or proteinbased coordinates for mutations (Supp. Note Ib). The use of the CGI can help addressing questions raised in different oncology research settings. A newly sequenced group of tumors may be readily interpreted, as exemplified with the pan-cancer cohort presented in this article. The application of the CGI to the mutations profiled across the whole exomes of these tumors delivered a catalog of putative driver alterations across its 28 cancer types (made available through http://www.intogen.org) (Suppl Note VII). The potential of a comprehensive analysis of individual alterations is illustrated by the identification of uncommon events that may be exploited by drug repurposing opportunities ( Figure 3B and Supp Note VII). Overall, the CGI identified 5.2% and 3.5% of the samples in the cohort with genomic alterations that are biomarkers of drug sensitivity used in the clinical practice (FDA-approved or international guidelines) or reported in late (phases III-IV) clinical trials, respectively. When considering biomarkers supported by lower levels of clinical relevance, a total of 62% of the tumors exhibited at least one potentially actionable alteration, a number that largely varied across cancer types ( Figure 3C and Supp Note VII). However, this cohort mostly includes samples sequenced at diagnosis and thus they may not reflect the type of tumors that are evaluated by molecular oncology boards at present. We also applied the CGI to the sequencing data of 17,642 tumors recently released by the GENIE project, which gathers more advanced cancers profiled by targeted panels 21 .
The CGI identified 8% and 6% in that cohort exhibiting biomarkers of drug sensitivity used in clinical practice or reported in late clinical trials, and overall 72% of these tumors exhibited at least one actionable alteration supported by any level of evidence ( Figure 3D and Supp Note VII). In addition, the GENIE cohort exhibited more genomic biomarkers of drug resistance, as expected from tumors with a higher proportion of recurrent/relapse patients (Supp Note VII). These analyses provide a comprehensive state-of-the-art snapshot of the putative genomic drivers of cancer and the landscape of genomic guided therapies as it stands today.
On the other hand, the application of the CGI to analyze the results of drug response observed in tumors with different genomic architecture could contribute to the discovery of novel genomic biomarkers of drug sensitivity or resistance. On detail, the distinction between driver and passenger events allows the development of better predictive models 22 . In the clinical setting, application of the CGI to analyze the list of alterations detected in a patient's tumor could support decision-making in multiple scenarios, especially in cases of variants of unknown significance that may have implications for response to therapy. Early clinical adopters of the CGI used the resource to support the final decision of the most appropriate clinical trial to enroll cancer patients or explore potential drug re-purposing opportunities for pediatric tumors (see Supp.
Note VIII).
Crucial to the performance of the CGI are the maintenance and further development of its two distinct types of resources: the repositories of accumulated knowledge and the bioinformatics methods. As new tumor cohorts are re-sequenced and analyzed, our medium-term plans include further development of the catalogs of cancer genes and oncogenic mutations, including both new malignancies and new genomic elements. In particular, the possibility to identify non-coding cancer drivers 23 institutions, including our own. We envision that individual databases will continue to be maintained to fulfill specific needs 24 , but our long-term impact will largely rely, first, on the establishment of international standards for the collection of data relevant to associations between cancer variant-clinical outcome and, second, on our collective success in encouraging the community to share such knowledge.
In summary, the CGI is a versatile platform that automates the steps we propose for the interpretation of cancer genomes, annotating the potential of the alterations detected in human tumors as cancer drivers and their possible effect on treatment response, according to current levels of evidence. The characteristics of the CGI, and the commitment to maintain it as part of a community effort to keep the resource up-to-date with evolving knowledge, allow its establishment as a widely disseminated, easy-to-use tool for both pre-clinical and translational cancer research settings.
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